1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. (23rd October 2018) - Reck, M; Wehler, T; Orlandi, F; Nogami, N; Barone, C; Moro-Sibilot, D; Shtivelband, M; González Larriba, J L; Rothenstein, J; Frueh, M; Shankar, G; Lee, A; et al.